196 related articles for article (PubMed ID: 32075053)
1. Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer.
Winn JS; Hasse Z; Slifker M; Pei J; Arisi-Fernandez SM; Talarchek JN; Obeid E; Baldwin DA; Gong Y; Ross E; Cristofanilli M; Alpaugh RK; Fernandez SV
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32075053
[TBL] [Abstract][Full Text] [Related]
2. Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients.
Keup C; Benyaa K; Hauch S; Sprenger-Haussels M; Tewes M; Mach P; Bittner AK; Kimmig R; Hahn P; Kasimir-Bauer S
Cell Mol Life Sci; 2020 Feb; 77(3):497-509. PubMed ID: 31254045
[TBL] [Abstract][Full Text] [Related]
3. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
[TBL] [Abstract][Full Text] [Related]
4. Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC).
Gong Y; Nagarathinam R; Arisi MF; Gerratana L; Winn JS; Slifker M; Pei J; Cai KQ; Hasse Z; Obeid E; Noriega J; Sebastiano C; Ross E; Alpaugh K; Cristofanilli M; Fernandez SV
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445631
[TBL] [Abstract][Full Text] [Related]
5. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
[TBL] [Abstract][Full Text] [Related]
6. Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
Chen TW; Hsiao W; Dai MS; Lin CH; Chang DY; Chen IC; Wang MY; Chang SH; Huang SM; Cheng AL; Wu KW; Tan KT; Lu YS
Breast Cancer Res Treat; 2023 Oct; 201(3):377-385. PubMed ID: 37344660
[TBL] [Abstract][Full Text] [Related]
7. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
[TBL] [Abstract][Full Text] [Related]
8. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
[TBL] [Abstract][Full Text] [Related]
9. Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen.
Jansen MP; Martens JW; Helmijr JC; Beaufort CM; van Marion R; Krol NM; Monkhorst K; Trapman-Jansen AM; Meijer-van Gelder ME; Weerts MJ; Ramirez-Ardila DE; Dubbink HJ; Foekens JA; Sleijfer S; Berns EM
Oncotarget; 2016 Jul; 7(28):43412-43418. PubMed ID: 27270325
[TBL] [Abstract][Full Text] [Related]
10. Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma.
Cowzer D; White JB; Chou JF; Chen PJ; Kim TH; Khalil DN; El Dika IH; Columna K; Yaqubie A; Light JS; Shia J; Yarmohammadi H; Erinjeri JP; Wei AC; Jarnagin W; Do RKG; Solit DB; Capanu M; Shah RH; Berger MF; Abou-Alfa GK; Harding JJ
JCO Precis Oncol; 2023 Sep; 7():e2300272. PubMed ID: 37769223
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer.
Liu MC; MacKay M; Kase M; Piwowarczyk A; Lo C; Schaeffer J; Finkle JD; Mason CE; Beaubier N; Blackwell KL; Park BH
JCO Precis Oncol; 2022 Jun; 6(1):e2100321. PubMed ID: 35721584
[TBL] [Abstract][Full Text] [Related]
12. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
13. Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing.
Masunaga N; Kagara N; Motooka D; Nakamura S; Miyake T; Tanei T; Naoi Y; Shimoda M; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2018 Jan; 167(1):49-58. PubMed ID: 28905136
[TBL] [Abstract][Full Text] [Related]
14. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
Liang DH; Ensor JE; Liu ZB; Patel A; Patel TA; Chang JC; Rodriguez AA
Breast Cancer Res Treat; 2016 Jan; 155(1):139-49. PubMed ID: 26667234
[TBL] [Abstract][Full Text] [Related]
15. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.
Chae YK; Davis AA; Carneiro BA; Chandra S; Mohindra N; Kalyan A; Kaplan J; Matsangou M; Pai S; Costa R; Jovanovic B; Cristofanilli M; Platanias LC; Giles FJ
Oncotarget; 2016 Oct; 7(40):65364-65373. PubMed ID: 27588476
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
Yang X; Zhang K; Zhang C; Peng R; Sun C
BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027
[TBL] [Abstract][Full Text] [Related]
17. Identification of driver genes and somatic mutations in cell-free DNA of patients with pulmonary lymphangioleiomyomatosis.
Zhang L; Wang MJ; Wang W; Zhao JY; Wu JL; Liu YP; Zhu H; Qu JM; Zhou M
Int J Cancer; 2020 Jan; 146(1):103-114. PubMed ID: 31199508
[TBL] [Abstract][Full Text] [Related]
18. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
[TBL] [Abstract][Full Text] [Related]
19. Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference.
Jensen K; Konnick EQ; Schweizer MT; Sokolova AO; Grivas P; Cheng HH; Klemfuss NM; Beightol M; Yu EY; Nelson PS; Montgomery B; Pritchard CC
JAMA Oncol; 2021 Jan; 7(1):107-110. PubMed ID: 33151258
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
